Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
about
Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administrationArtemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria: a systematic review and meta-analysis of day 7 lumefantrine concentrations and therapeutic response using individual patient dataThe effect of dosing regimens on the antimalarial efficacy of dihydroartemisinin-piperaquine: a pooled analysis of individual patient dataIntermittent preventive treatment for malaria in Papua New Guinean infants exposed to Plasmodium falciparum and P. vivax: a randomized controlled trialAge, Weight, and CYP2D6 Genotype Are Major Determinants of Primaquine Pharmacokinetics in African Children.Longitudinal study on Plasmodium falciparum gametocyte carriage following artemether-lumefantrine administration in a cohort of children aged 12-47 months living in Western Kenya, a high transmission areaTime-to-infection by Plasmodium falciparum is largely determined by random factors.Pharmacokinetic predictors for recurrent malaria after dihydroartemisinin-piperaquine treatment of uncomplicated malaria in Ugandan infantsEarly variations in plasmodium falciparum dynamics in Nigerian children after treatment with two artemisinin-based combinations: implications on delayed parasite clearance.Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda.Pharmacokinetic and pharmacodynamic characteristics of a new pediatric formulation of artemether-lumefantrine in African children with uncomplicated Plasmodium falciparum malariaCharacterization of treatment failure in efficacy trials of drugs against Plasmodium vivax by genotyping neutral and drug resistance-associated markers.Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination.Population pharmacokinetics of artemether, lumefantrine, and their respective metabolites in Papua New Guinean children with uncomplicated malaria.The use of paediatric artemisinin combinations in sub-Saharan Africa: a snapshot questionnaire survey of health care personnel.The interaction between artemether-lumefantrine and lopinavir/ritonavir-based antiretroviral therapy in HIV-1 infected patients.Pharmacokinetic comparison of two piperaquine-containing artemisinin combination therapies in Papua New Guinean children with uncomplicated malaria.The efficacy and tolerability of artemisinin-piperaquine (Artequick®) versus artesunate-amodiaquine (Coarsucam™) for the treatment of uncomplicated Plasmodium falciparum malaria in south-central Vietnam.Population pharmacokinetic and pharmacodynamic modeling of amodiaquine and desethylamodiaquine in women with Plasmodium vivax malaria during and after pregnancy.Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.Antiretroviral Choice for HIV Impacts Antimalarial Exposure and Treatment Outcomes in Ugandan Children.Population Pharmacokinetics and Pharmacodynamics of Lumefantrine in Young Ugandan Children Treated With Artemether-Lumefantrine for Uncomplicated Malaria.Disposition of amodiaquine and desethylamodiaquine in HIV-infected Nigerian subjects on nevirapine-containing antiretroviral therapyThe pharmacokinetic evaluation of artemisinin drugs for the treatment of malaria in paediatric populations.The pharmacogenetics of antimalaria artemisinin combination therapy.Pharmacokinetic profile of artemisinin derivatives and companion drugs used in artemisinin-based combination therapies for the treatment of Plasmodium falciparum malaria in children.Oil-Fortified Maize Porridge Increases Absorption of Lumefantrine in Children with Uncomplicated Falciparum Malaria.Comparable lumefantrine oral bioavailability when co-administered with oil-fortified maize porridge or milk in healthy volunteers.Endoperoxide Drug Cross-Resistance Patterns for Plasmodium falciparum Exhibiting an Artemisinin Delayed-Clearance Phenotype.The clinical impact of combining intermittent preventive treatment with home management of malaria in children aged below 5 years: cluster randomised trial.Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator's product.Proguanil and cycloguanil are organic cation transporter and multidrug and toxin extrusion substrates.Coartemether induced oxidative and hepatic damage in Plasmodium berghei strain Anka infected mice.Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.Pharmacokinetic considerations for use of artemisinin-based combination therapies against falciparum malaria in different ethnic populations.Population Pharmacokinetic properties of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria.Pharmacokinetics and safety profile of artesunate-amodiaquine co-administered with antiretroviral therapy in malaria uninfected HIV-positive Malawian adults.Semi-quantitative measurement of the antimalarial lumefantrine from untreated dried blood spots using LC-MS/MS.Artemether-lumefantrine dosing for malaria treatment in young children and pregnant women: A pharmacokinetic-pharmacodynamic meta-analysis.
P2860
Q21034080-3BDC9E03-9BEB-4C8B-81BA-E7DDFA9A4BAAQ26783646-309F84B4-39DA-4184-9646-95E2D8EA03A5Q26822489-FFF5A13D-6739-4E32-939D-A58AA5D48EB8Q28481649-043446EA-E491-4233-8C29-3B4E2A577A0EQ33601837-6BACD2FE-C660-468D-8F00-6299A05F4D44Q33928116-1269FBFB-7F8D-4919-A260-755C1A39756BQ35030175-05BD7788-58DA-427C-AF5D-FE37474B5FD2Q35055212-87D568C6-9516-43B2-A3EB-F40D6EE6C32FQ35154559-17FDF906-AFEA-49A3-8B44-6A445A748899Q35188480-9530A8C5-C29B-4BED-8084-6D08C7811737Q35191375-B786E3CF-001E-41DA-8E56-AE547163979FQ35191546-6B60AB30-62D9-44E0-A1EE-4B9C6E2BD8DFQ35224221-F3BD307A-CE63-4205-B3E9-29C6832AE977Q35363704-3DCEB757-8A08-4DF9-BB35-B50F2EFC9E65Q35761615-AF192F24-CCFE-4DE8-91DB-D65BC98EA464Q35906361-5F4C7B03-CF49-4DA0-973A-EA3BBCD885E9Q36018642-43FB5E5F-7B4E-4BDB-98B4-70007A3F4082Q36138872-A009B386-3472-4400-8743-20AD33AE8792Q36364248-DAC319B2-A0CE-481C-B4CC-9881D9E4DD71Q36438820-B161A1C9-F736-4934-A12C-B7EFD948F143Q36876420-1F1469CE-1E26-4EB1-99AD-B7269D5B535AQ37096787-7365636C-7924-4621-8CEB-C7CB0B900E22Q37279764-6E272A92-B83F-442F-8221-B8C27BE7D1E6Q37688260-893595D3-ED6A-4B19-815E-AF4D9D43186DQ37841602-0EB6651E-1578-45EB-9EA9-06B3BDB0B463Q37928680-861331CC-323A-455A-ACE4-414FF08F5E4FQ38071558-C1ED6808-96DB-456A-95F8-B4E4E50707ECQ38852053-81A8C420-25C2-4ECC-AC52-61A93C3BA1AFQ38865815-6CF81D53-402A-43D5-A17E-369A56985C79Q39418139-1A5D0887-0B4B-4D81-8434-786E91181AAAQ40340666-2674195C-51EF-49D3-9F83-C599AD49CF66Q41866966-4A3BC204-70E3-4A8B-A403-5C0BB2FB7314Q42643524-01B6D09A-71B3-4E36-9595-00EC6B55E9CFQ44269476-0B5FC03B-3435-47AE-8386-90046BFE49F1Q46398741-53E4BEC0-C3F6-45B2-AC35-D9CB233576E0Q46405195-6044C0DC-35EC-4C31-AA0D-DA013D691572Q49791979-325025D3-990E-4094-95E1-41EB2F4591F2Q54212174-BACB8460-869C-4453-AADD-93652C3A6A01Q54235937-16A37FFB-B2BE-4D4D-A0C7-28E995FA7F63Q55449589-A947F358-2F52-483C-A8F3-D3E0127F564B
P2860
Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda.
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@ast
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@en
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@nl
type
label
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@ast
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@en
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@nl
prefLabel
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@ast
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@en
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@nl
P2093
P2860
P50
P921
P356
P1476
Pharmacokinetics of artemether ...... n children in Kampala, Uganda.
@en
P2093
Anna Annerberg
Bryan McGee
Francesca Aweeka
Joan N Kalyango
Niklas Lindegardh
Polina German
Sunil Parikh
Tamara D Clark
Troy Drysdale
P2860
P356
10.1128/AAC.00679-09
P407
P577
2009-10-19T00:00:00Z